Author

Robert J. Nichols

Primary ORCID profile (0000-0002-8476-0554 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Robert J. NicholsiD1 paper · University of California, San Francisco

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1

Frequent Co-Authors

Abby Marquez· 1 shared Adrian L. Gill· 1 shared Carlos Stahlhut· 1 shared Christopher J. Schulze· 1 shared Christos Tzitzilonis· 1 shared Daphne Hsieh· 1 shared David Wildes· 1 shared Elena S. Koltun· 1 shared

Activity by Year

2017-2017 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abby Marquez

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintSep 14, 2017

Efficacy of SHP2 phosphatase inhibition in cancers with nucleotide-cycling oncogenic RAS, RAS-GTP dependent oncogenic BRAF and NF1 loss

Robert J. Nichols, Franziska Haderk, Carlos Stahlhut…·Trever G. Bivona

This study shows that inhibiting SHP2 phosphatase effectively targets cancers driven by nucleotide-cycling RAS, RAS-GTP dependent BRAF, or NF1 loss by disrupting RAS-RAF-MEK-ERK signaling.

DOI 10.1101/188730

humanexperimental assay

𝕏 PostBluesky